All Stories

  1. The intriguing role of platelets as custodians of brain-derived neurotrophic factor
  2. Alpha-2-macroglobulin prevents platelet aggregation induced by brain-derived neurotrophic factor
  3. Multicenter evaluation of light transmission platelet aggregation reagents: communication from the ISTH SSC Subcommittee on Platelet Physiology
  4. Consensus report on markers to distinguish procoagulant platelets from apoptotic platelets: communication from the Scientific and Standardization Committee of the ISTH
  5. Soluble p75 neurotrophic receptor as a reliable biomarker in neurodegenerative diseases: what is the evidence?
  6. Consensus report on flow cytometry for platelet function testing in thrombocytopenic patients: communication from the SSC of the ISTH
  7. Assessment of Platelet Function by High-Throughput Screening Light Transmission Aggregometry: Optimul Assay
  8. Plasminogen Activator Inhibitor-1–Positive Platelet-Derived Extracellular Vesicles Predicts MACE and the Proinflammatory SMC Phenotype
  9. Expert opinion on the use of platelet secretion assay for the diagnosis of inherited platelet function disorders: Communication from the ISTH SSC Subcommittee on Platelet Physiology
  10. Antiplatelet Therapy in Atherothrombotic Diseases: Similarities and Differences Across Guidelines
  11. Assessing cardiometabolic parameter monitoring in inpatients taking a second-generation antipsychotic: The CAMI-SGA study – a cross-sectional study
  12. Aspirin for Primary Cardiovascular Prevention in Patients with Diabetes: Uncertainties and Opportunities
  13. Clinical Correlates Identify ProBDNF and Thrombo-Inflammatory Markers as Key Predictors of Circulating p75NTR Extracellular Domain Levels in Older Adults
  14. Rare missense variants in Tropomyosin‐4 (TPM4) are associated with platelet dysfunction, cytoskeletal defects, and excessive bleeding
  15. Editorial: Established and Novel Roles of Platelets in Health and Disease
  16. Antiplatelet Therapy for Atherothrombotic Disease in 2022—From Population to Patient-Centered Approaches
  17. A randomized double-blind feasibility study comparing cetirizine and diphenhydramine in the prevention of paclitaxel-associated infusion-related reactions: the PREMED-F1 study
  18. Current and Novel Antiplatelet Therapies for the Treatment of Cardiovascular Diseases
  19. Consensus recommendations on flow cytometry for the assessment of inherited and acquired disorders of platelet number and function: Communication from the ISTH SSC Subcommittee on Platelet Physiology
  20. Differences in platelet‐rich plasma composition influence bone healing
  21. The brain-derived neurotrophic factor prompts platelet aggregation and secretion
  22. Brain-Derived Neurotrophic Factor Mitigates the Association Between Platelet Dysfunction and Cognitive Impairment
  23. Effect of Paper Versus Digital Reading in Health Professional Education: A Systematic Review and Meta-Analysis
  24. The effect of aging on the bone healing properties of blood plasma
  25. Differential modulation of polyunsaturated fatty acids in patients with myocardial infarction treated with ticagrelor or clopidogrel
  26. The ISTH bleeding assessment tool as predictor of bleeding events in inherited platelet disorders: Communication from the ISTH SSC Subcommittee on Platelet Physiology
  27. Dual antiplatelet therapy (PEGASUS) vs. dual pathway (COMPASS): a head-to-head in vitro comparison
  28. Platelet Function in Viral Immunity and SARS-CoV-2 Infection
  29. Platelet Quiescence in Patients With Acute Coronary Syndrome Undergoing Coronary Artery Bypass Graft Surgery
  30. Tissue-Specificity of Antibodies Raised Against TrkB and p75NTR Receptors; Implications for Platelets as Models of Neurodegenerative Diseases
  31. Severity of Megakaryocyte‐Driven Osteosclerosis in Mpig6b ‐Deficient Mice Is Sex‐Linked
  32. Acetylcholinesterase inhibitors and risk of bleeding and acute ischemic events in non‐hypertensive Alzheimer's patients
  33. Implications of the Antiplatelet Therapy Gap Left with Discontinuation of Prasugrel in Canada
  34. Platelets Selectively Regulate the Release of BDNF, But Not That of Its Precursor Protein, proBDNF
  35. Postoperative Administration of the Acetylcholinesterase Inhibitor, Donepezil, Interferes with Bone Healing and Implant Osseointegration in a Rat Model
  36. Advances in Platelet Function Testing—Light Transmission Aggregometry and Beyond
  37. Platelet count and disease – editorial policy
  38. Effects of reading media on reading comprehension in health professional education
  39. Differential correlation of serum BDNF and microRNA content in rats with rapid or late onset of heavy alcohol use
  40. Head-to-Head Comparison of Consensus-Recommended Platelet Function Tests to Assess P2Y12 Inhibition—Insights for Multi-Center Trials
  41. Differential Correlation of Serum BDNF and microRNA Content in Rats with Rapid or Late Onset of Heavy Alcohol Use
  42. Validation of the ISTH/SSC bleeding assessment tool for inherited platelet disorders: A communication from the Platelet Physiology SSC
  43. A Critical Comparison of Canadian and International Guidelines Recommendations for Antiplatelet Therapy in Coronary Artery Disease
  44. Platelet Function in Aging
  45. Study of the bioaccumulation of tinzaparin in renally impaired patients when given at prophylactic doses - The STRIP study
  46. Clinical Tests of Platelet Function
  47. 750
  48. Increased platelet reactivity and platelet–leukocyte aggregation after elective coronary bypass surgery
  49. An interview with Professor Gus Born
  50. Clinical importance of thrombocytopenia in patients with acute coronary syndromes: a systematic review and meta-analysis
  51. 2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Focused Update of the Guidelines for the Use of Antiplatelet Therapy
  52. Platelets at the heart of therapy
  53. Ischemic and bleeding outcomes after coronary artery bypass grafting among patients initially treated with a P2Y12 receptor antagonist for acute coronary syndromes: Insights on timing of discontinuation of ticagrelor and clopidogrel prior to surgery
  54. Personalizing antiplatelet therapies: What have we learned from recent trials?
  55. Tailored antiplatelet therapy in high-risk ACS patients treated with PCI stenting: lessons from the ANTARCTIC trial
  56. Mice Lacking the Inhibitory Collagen Receptor LAIR-1 Exhibit a Mild Thrombocytosis and Hyperactive PlateletsHighlights
  57. PREVALENCE AND CLINICAL IMPACT OF THROMBOCYTOPENIA IN PATIENTS WITH ACUTE CORONARY SYNDROMES: A SYSTEMATIC REVIEW AND META-ANALYSIS
  58. Platelet function one and three months after coronary bypass surgery in relation to once or twice daily dosing of acetylsalicylic acid
  59. Platelet Function Tests
  60. Tests of Platelet Function
  61. ISCHEMIC AND BLEEDING OUTCOMES AFTER CORONARY ARTERY BYPASS GRAFTING AMONG PATIENTS INITIALLY TREATED WITH A P2Y12 RECEPTOR ANTAGONIST FOR ACUTE CORONARY SYNDROMES - INSIGHTS ON THE USE OF TICAGRELOR VERSUS CLOPIDOGREL PRIOR TO SURGERY
  62. ISCHEMIC AND BLEEDING OUTCOMES AFTER CORONARY ARTERY BYPASS GRAFTING AMONG PATIENTS INITIALLY TREATED WITH A P2Y12 RECEPTOR ANTAGONIST FOR ACUTE CORONARY SYNDROMES - INSIGHTS ON TIMING OF DISCONTINUATION OF TICAGRELOR AND CLOPIDOGREL PRIOR TO SURGERY
  63. The Effects of Different Aspirin Dosing Frequencies and the Timing of Aspirin Intake in Primary and Secondary Prevention of Cardiovascular Disease: A Systematic Review
  64. Platelet function testing as a biomarker for efficacy of antiplatelet drugs
  65. Whole exome sequencing identifies genetic variants in inherited thrombocytopenia with secondary qualitative function defects
  66. Platelet function tests
  67. Vorapaxar and diplopia: Possible off-target PAR-receptor mismodulation
  68. Is platelet transfusion the solution to reverse platelet inhibition in patients on triple antiplatelet therapy?
  69. SLFN14 mutations underlie thrombocytopenia with excessive bleeding and platelet secretion defects
  70. The role of platelets in the recruitment of leukocytes during vascular disease
  71. Investigating the effectiveness of different aspirin dosing regimens and the timing of aspirin intake in primary and secondary prevention of cardiovascular disease: protocol for a systematic review
  72. Impact of preoperative use of P2Y12 receptor inhibitors on clinical outcomes in cardiac and non-cardiac surgery: A systematic review and meta-analysis
  73. The prognostic utility of tests of platelet function for the detection of ‘aspirin resistance’ in patients with established cardiovascular or cerebrovascular disease: a systematic review and economic evaluation
  74. Use of next‐generation sequencing and candidate gene analysis to identify underlying defects in patients with inherited platelet function disorders
  75. Diversity and impact of rare variants in genes encoding the platelet G protein-coupled receptors
  76. Methodological issues and recommendations for systematic reviews of prognostic studies: an example from cardiovascular disease
  77. Evidence of platelet sensitization to ADP following discontinuation of clopidogrel therapy in patients with stable coronary artery disease
  78. A novel mutation in the P2Y12 receptor and a function‐reducing polymorphism in protease‐activated receptor 1 in a patient with chronic bleeding
  79. Evaluation of a whole blood remote platelet function test for the diagnosis of mild bleeding disorders
  80. Characterization of multiple platelet activation pathways in patients with bleeding as a high-throughput screening option: use of 96-well Optimul assay
  81. A novel thromboxane A2 receptor N42S variant results in reduced surface expression and platelet dysfunction
  82. Enrichment of FLI1 and RUNX1 mutations in families with excessive bleeding and platelet dense granule secretion defects
  83. Utility of the ISTH bleeding assessment tool in predicting platelet defects in participants with suspected inherited platelet function disorders
  84. Pharmacogenomics in cardiovascular disease: focus on aspirin and ADP receptor antagonists
  85. Genotyping and phenotyping of platelet function disorders
  86. Testing Platelet Function
  87. Simultaneous measurement of ATP release and LTA does not potentiate platelet aggregation to epinephrine
  88. Microsatellite markers as a rapid approach for autozygosity mapping in Hermansky-Pudlak syndrome: Identification of the second HPS7 mutation in a patient presenting late in life
  89. OC-13 Investigation of underlying platelet function defects in patients with unexplained menorrhagia
  90. Protocol for a systematic review of the diagnostic and prognostic utility of tests currently available for the detection of aspirin resistance in patients with established cardiovascular or cerebrovascular disease
  91. Clinical Tests of Platelet Function
  92. G6f-Like Is an ITAM-Containing Collagen Receptor in Thrombocytes
  93. Platelet Turnover in Atherothrombotic Disease
  94. Evaluation of participants with suspected heritable platelet function disorders including recommendation and validation of a streamlined agonist panel
  95. Advances in monitoring of aspirin therapy
  96. Aspirin twice a day keeps new COX-1 at bay
  97. 50th anniversary of the discovery of ibuprofen: an interview with Dr Stewart Adams
  98. Genetic determinants of response to aspirin: Appraisal of 4 candidate genes
  99. Heterogeneity in platelet cyclooxygenase inhibition by aspirin in coronary artery disease
  100. Beware of being caught on the rebound
  101. Why an aspirin a day no longer keeps the doctor away …
  102. Platelet count, not oxidative stress, may contribute to inadequate platelet inhibition by aspirin
  103. Insights into the interpretation of light transmission aggregometry for evaluation of platelet aggregation inhibition by clopidogrel
  104. Prevalence of Unresponsiveness to Aspirin and/or Clopidogrel in Patients With Stable Coronary Heart Disease
  105. Evaluation of the platelet count drop method for assessment of platelet function in comparison with “gold standard” light transmission aggregometry
  106. Week-Long High-Maintenance Dose Clopidogrel Regimen Achieves Better Platelet Aggregation Inhibition than a Standard Loading Dose before Percutaneous Coronary Intervention: Results of a Double-Blind, Randomized Clinical Trial
  107. Possibility of a rebound phenomenon following antiplatelet therapy withdrawal: A look at the clinical and pharmacological evidence
  108. Response to aspirin in healthy individuals. Cross-comparison of light transmission aggregometry, VerifyNow system, platelet count drop, thromboelastography (TEG) and urinary 11-dehydrothromboxane B2
  109. Comparison of four tests to assess inhibition of platelet function by clopidogrel in stable coronary artery disease patients
  110. Assessment of VerifyNow P2Y12 Assay Accuracy in Evaluating Clopidogrel-Induced Platelet Inhibition
  111. Comparison of different methods of measurement of aspirin resistance: using the appropriate statistic: reply
  112. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease
  113. Aspirin resistance: Truth or dare